In lean MASLD with visceral adiposity (and/or high-risk metabolic/genetic features) in an already physically active patient, when do you recommend additional weight loss versus focusing on diet quality and central adiposity reduction, and how do you monitor to avoid clinically meaningful loss of lean mass?

1 Answers

Mednet Member

Hepatology · Penn State College of Medicine

In lean MASLD, current practice guidance would prioritize reduction of visceral adiposity and improvement in metabolic health rather than pursuing arbitrary WL targets, particularly in patients who are already physically active and have a normal BMI. In this setting, I focus on diet quality (Mediter...